Logo for Inventiva S.A.

Inventiva Investor Relations Material

Latest events

Logo for Inventiva

Q2 2024

25 Sep, 2024
Logo for Inventiva

Q1 2024

21 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Inventiva S.A.

Access all reports
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of orally administered small molecule therapies for the treatment of serious diseases. The company's research primarily targets conditions related to fibrosis, lysosomal storage disorders, and oncology. Inventiva leverages its proprietary technology platform to identify and develop novel compounds that modulate nuclear receptors, transcription factors, and epigenetic regulation. The company's lead products are developed through strategic collaborations with other pharmaceutical companies, aiming to advance these therapies through clinical trials and regulatory approval. The company is headquartered in Daix, France, and its shares are listed on the Nasdaq.